CN1931190A - Toad skin extract and its medicine prepn and their prepn - Google Patents
Toad skin extract and its medicine prepn and their prepn Download PDFInfo
- Publication number
- CN1931190A CN1931190A CNA200610096075XA CN200610096075A CN1931190A CN 1931190 A CN1931190 A CN 1931190A CN A200610096075X A CNA200610096075X A CN A200610096075XA CN 200610096075 A CN200610096075 A CN 200610096075A CN 1931190 A CN1931190 A CN 1931190A
- Authority
- CN
- China
- Prior art keywords
- extract
- cutis bufonis
- preparation
- amount
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is toad skin extract and its medicine preparation and their preparation, and features that the toad skin extract has indole alkaloid content of 25-40 % and total cinobufagin and lipobufogenin content of 0.01-0.05 %. During the preparation, the indole alkaloid content and the total cinobufagin and lipobufogenin content is raised as possible. The said Chinese medicine preparation has high quality, small size, small dosage, high clinical curative effect and lowered side effect.
Description
Technical field:
The present invention relates to a kind of Cutis Bufonis extract, this preparation method of extract and described Cutis Bufonis extract add the various Chinese medicine preparation of making behind the pharmaceutic adjuvant.
Background technology:
Cutis Bufonis is the dry whole bark of Bufonidae animal Bufo siccus Bufo bufo gargarizans Cantor or Bufo melanostictus Bufomelanostictus Schneider.The chemical constituent of Cutis Bufonis mainly contains cinobufagin, bufogenin, Toadpoison Medicine etc., and by them and succinic acid, succinic acid, the esters that arginine etc. form, as Toadpoison Medicine-3-succinyl arginine ester, bufotalien-3-succinyl arginine ester, cinobufacin-3-succinyl arginine ester, bufogenin-3-succinyl arginine ester etc.Also contain indoles alkaloid, as 5-hydroxy tryptamine, bufotenine, the Bufo siccus quaternary amine, Bufo siccus thiophene peace dehydrobufotenines etc. still contain aminoacid, polypeptide and phytosterin compound in addition.Cutis Bufonis has heat-clearing and toxic substances removing, and the bloated clearly effect of diuretic is used for the treatment of carbuncle, toxic swelling, scrofula, tumor, infantile malnutrition abdominal distention, chronic tracheitis etc.At present, the Cutis Bufonis extract preparation mainly contains HUACHANSU ZHUSHEYE, cinobufacin tablet, cinobufacin oral liquid etc., wherein a kind of especially traditional biological medicine preparation of HUACHANSU ZHUSHEYE, be widely used in clinical, have detoxifcation, detumescence, analgesic effect, be mainly used in treatment middle and advanced stage tumor, chronic hepatitis B clinically, also be used for the treatment of diseases such as intractable singultus, verruca plana and psoriasis.
Relevant at present report has: its Cutis Bufonis extraction process of " a kind of cinobufacin capsule and preparation method thereof " (number of patent application 98103562) is a decoction and alcohol sedimentation technique, though technology is simple, impurity is more." a kind of nanometer cinobufacin preparation medicine and preparation method thereof " (number of patent application 00136668) though this method microwave extracting, without separation, still impurity is more.This method is strict for process equipment simultaneously, is difficult to carry out at present.A kind of in addition " cinobufotalin lyophilized powder and preparation method thereof " (number of patent application 200410083994.4), though Cutis Bufonis is through ethanol extraction in the technology, purification with macroreticular resin, but use 80% ethanol extraction in this technology, and the macroporous absorption of using is that the concentration of alcohol of the resin macroporous adsorbent resin eluting of nonpolar or low pole is 35%～45%, so its paste-forming rate is still than higher, 1.20%～1.38% (w/w), the impurities amount is still many." a kind of new cinobufogenin freeze-drying powder injection and preparation method thereof and method of quality control " (number of patent application 200510061288.4), wherein Cutis Bufonis extract is a decoction and alcohol sedimentation technique, and it is big that the problem of existence remains paste-forming rate, and impurity content is many." a kind of preparation method of cinobufogenin freeze-drying powder injection " (number of patent application 200510115451.0), wherein Cutis Bufonis extract is a decoction and alcohol sedimentation technique still, and extracts active ingredients is incomplete, and paste-forming rate is big, and impurity content is many.
As the major product of Cutis Bufonis in the market, HUACHANSU ZHUSHEYE, the preparation technology of its Cutis Bufonis extract is a water extract-alcohol precipitation, paste-forming rate is big, the impurity content height, wherein the indoles total alkaloid content only is 7.0%～10.0%, and cinobufagin and bufogenin total amount only are 0.001%～0.005%.
Summary of the invention:
The present invention is for avoiding above-mentioned existing in prior technology weak point, a kind of Cutis Bufonis extract, its pharmaceutical preparation and preparation method thereof are provided, guaranteeing under the prerequisite of drug effect, improving the content of indole total alkaloids and cinobufagin and bufogenin in the Cutis Bufonis extract as far as possible.By the raw materials quality of effective control Chinese medicine preparation, reach that volumes of formulation is little, consumption is few, improve clinical efficacy, reduce the effect of side effect.
The objective of the invention is to realize by the following technical solutions:
Cutis Bufonis extract of the present invention, the content that it is characterized in that indoles alkaloid in the described extract is 25%～40%, cinobufagin and bufogenin total amount are 0.01%～0.05%.
The Chinese medicine preparation of Cutis Bufonis extract of the present invention is characterized in that described Chinese medicine preparation is is the medicine active ingredient with described Cutis Bufonis extract, adds injection, infusion solution, the powder ampoule agent for injection made behind the pharmaceutic adjuvant.
The preparation method of Cutis Bufonis extract of the present invention is characterized in that operating as follows:
A, get dry maxima skin, clean, add 6～7 times of amount 85% methanol or ethanol or acetone and soaked 2 hours, reflux, extract, 60 minutes is put coldly, filters, and residue adds 5～6 times of amount 85% methanol or ethanol or acetone, and reflux, extract, 50 minutes is put coldly, filters merging filtrate;
B, step a gained filtrate add the water that is equivalent to 1～2 times of amount of medical material amount and dissolve through being evaporated to solvent-free flavor, leave standstill 24 hours after-filtration;
C, step b gained filtrate are gone up macroporous adsorptive resins, adopt Semi-polarity or polar macroporous adsorption resin, earlier with 2～3 times of column volume water elutions, 3～4 times of column volume 50%～65% ethanol elutions of reuse are collected ethanol elution, concentrating under reduced pressure, 60 ℃ of vacuum dryings get Cutis Bufonis extract.
The feature of the preparation method of Cutis Bufonis extract of the present invention is that also described Semi-polarity or polar macroporous adsorption resin are polystyrene type or crosslink propylene resinae, comprises HPD-400, DM301 or HPD-600, and granularity is 0.3mm～1.25mm.
Beneficial effect of the present invention is embodied in:
1, Cutis Bufonis extract of the present invention is with effective ingredient indoles total alkaloids, the content of cinobufagin and bufogenin characterizes, and effects such as significant antitumor and treatment chronic hepatitis B are arranged with cinobufacin injection, cinobufacin infusion solution and the injection cinobufotalin lyophilized powder of this characteristic manner.
2, Cutis Bufonis extract of the present invention adopts 85% methanol or ethanol or acetone to extract, and effective ingredient indole total alkaloids and toadpoison esters composition are fully extracted, and compositions such as the big peptide class of molecular weight, protein are difficult to extract.Crude extract has been removed water-solubility impurity after macroporous adsorbent resin separates, enrichment effective ingredient.
3, the present invention is owing to working concentration when extracting is 85% solvent, and employing Semi-polarity or polar resin, thereby making the Cutis Bufonis extract paste-forming rate of gained be reduced to 0.2%～1.0%, the Chinese medicine preparation volume made from this Cutis Bufonis extract is little, dose is little, and is clinical easy to use.
4, the present invention can satisfy tumor and the hepatitis B patient demand to different dosage form.
The indoles Determination of Total Alkaloid is with reference to the magnificent Venenum Bufonis Injection version standard (WS of portion
3-B-3045) carry out, with the 5-hydroxy tryptamine reference substance, be developer with 15% pair-dimethylaminobenzaldehyde, recording this product with ultraviolet spectrophotometry, to contain the indoles total alkaloid content be 25%～40%.
The assay of cinobufagin and bufogenin is to measure with reference to HPLC method under Venenum Bufonis item of Chinese Pharmacopoeia version in 2005, and the total amount of cinobufagin and bufogenin is 0.01%～0.05% in this product as a result.
Following The pharmacological results is illustrated its drug action
1, anti-hepatitis B virus experimentation
1 order male sheldrake in age, body weight 45g ± 5g; DHB DHBV-DNA strong positive serum picks up from the Shanghai sheldrake ,-70 ℃ of preservations.
Get 1 age in days sheldrake, through lower limb shin intravenous injection Shanghai sheldrake DHBV-DNA positive serum, every 0.2ml.DHBV infected the 13rd day, and duckling is divided into 3 groups at random: HUACHANSU ZHUSHEYE group, cinobufacin transfusion group of the present invention that matched group, Anhui gold toad Pharmaceutical head office are produced, 10 every group.Press 2ml/kg body weight intravenous administration from sheldrake lower limb shin every day, and every day 1 time, continuous 10 days, positive controls was given and the equivalent normal saline.More than each group before administration, (promptly infected the 13rd day) respectively, after the administration behind the 5th day, administration behind the 10th day, drug withdrawal the 2nd day from duck lower limb venous blood collection, separation of serum ,-70 ℃ of preservations are standby.
Get above-mentioned serum point in the NC film, press the operation of nick translation test kit description, use
32P labelling DHBV-DNA probe is made the clear dot blot hybridization of Sanguis Anas domestica, and autoradiography diaphragm speckle is measured D value (the optical filter wavelength is 490nm) on microplate reader, calculate serum DHBV-DNA optical density.The result is as follows:
Table 1 cinobufacin in the duck body to the inhibitory action of DHBV-DNA (x ± s)
| Group | Dosage | D(490nm) | |||
| Before the administration | Administration 5 days | Administration 10 days | Drug withdrawal 3 days | ||
| Matched group HUACHANSU ZHUSHEYE group cinobufacin transfusion group | 1.19±0.27 1.40±0.38 1.34±0.22 | 0.91±0.39 1.36±0.41 1.23±0.31 | 0.87±0.57 0.72±0.34 *Δ 0.66±0.23 *Δ | 0.82±0.43 0.37±0.24 *Δ 0.30±0.19 **Δ | |
With before the self administration relatively:
*P＜0.05,
*P＜0.01; Compare with matched group:
ΔP＜0.05.
2, to mice transplanted tumor S
180The growth inhibited effect
Choose inoculation S
1807 days mice behind the oncocyte takes off neck and puts to death, and aseptic extraction ascites is transferred cell concentration to 1 * 10 with normal saline
7Individual/mL.Being inoculated in mice with every mice 0.2mL has the oxter subcutaneous, the preparation bearing mouse model.Tumor-bearing mice is divided into 3 groups at random: HUACHANSU ZHUSHEYE group, cinobufacin transfusion group of the present invention that matched group, Anhui gold toad Pharmaceutical head office are produced, 8 every group.Every day, mouse tail vein injection was administered once, and pressed 0.2ml/ administration, and every day 1 time, continuous 10 days, positive controls was given and the equivalent normal saline.Put to death mice on 11st, carefully peel off the tumor piece, claim tumor heavy, calculate tumour inhibiting rate.The results are shown in Table 2.
The magnificent Venenum Bufonis transfusion of table 2 is to S
180The influence that the tumor-bearing mice tumor weighs (x ± s)
| Group | Average tumor is heavy | Tumour inhibiting rate (%) |
| Matched group HUACHANSU ZHUSHEYE group cinobufacin transfusion group | 2.19±0.69 1.07±0.34 ** 0.99±0.29 ** | --- 51.1 55.6 |
Compare with matched group:
*P＜0.05,
*P＜0.01.
Below by the specific embodiment the present invention is further described:
The specific embodiment:
The content of indoles alkaloid is 25%～40% in the present embodiment Cutis Bufonis extract, and cinobufagin and bufogenin total amount are 0.01%～0.05%.
Present embodiment Cutis Bufonis extract Chinese medicine preparation is to be the medicine active ingredient with the Cutis Bufonis extract, adds injection, infusion solution, the powder ampoule agent for injection made behind the pharmaceutic adjuvant.
The preparation method of present embodiment Cutis Bufonis extract is to operate as follows:
1, get dry maxima skin, clean, add 6～7 times of amount 85% methanol or ethanol or acetone and soaked 2 hours, reflux, extract, 60 minutes is put coldly, filters, and residue adds 5～6 times of amount 85% methanol or ethanol or acetone, and reflux, extract, 50 minutes is put coldly, filters merging filtrate;
2, step 1 gained filtrate adds the water that is equivalent to 1～2 times of amount of medical material amount and dissolves through being evaporated to solvent-free flavor, leaves standstill 24 hours after-filtration;
3, step 2 gained filtrate is gone up macroporous adsorptive resins, adopts Semi-polarity or polar macroporous adsorption resin, specifically can be polystyrene type or crosslink propylene resinae, comprises HPD-400, DM301 or HPD-600, and granularity is 0.3mm～1.25mm.With 2～3 times of column volume water elutions, 3～4 times of column volume 50%～65% ethanol elutions of reuse are collected ethanol elution earlier, concentrating under reduced pressure, and 60 ℃ of vacuum dryings get Cutis Bufonis extract.
Embodiment 1:
Get dry maxima skin 500g, clean, add 6 times of amount 85% methanol and soaked 2 hours, reflux, extract, 60 minutes is put coldly, filters, and residue adds 5 times of amount 85% methanol eddies 50 minutes, puts cold filtration, merging filtrate.
Filtrate decompression is concentrated into does not have the alcohol flavor, adds to be equivalent to 1.5 times of water gaging dissolvings of medical material, places 24 hours, filters.
HPD-400 type macroporous adsorptive resins on the filtrate, earlier with 3 times of column volume water elutions, 4 times of column volume 50% ethanol elutions of reuse are collected ethanol elution, and concentrating under reduced pressure in 60 ℃ of vacuum dryings, gets Cutis Bufonis extract 4.0g.
Embodiment 2:
Get dry maxima skin 500g, clean, add 6 times of amount 85% soak with ethanol 2 hours, reflux, extract, 60 minutes is put coldly, filters, and residue adds 5 times of amount 85% alcohol reflux 50 minutes, puts coldly, filters merging filtrate.
Filtrate decompression is concentrated into does not have the alcohol flavor, adds and is equivalent to 2 times of water gagings of medical material, and dissolving was placed 24 hours, filtered.
HPD-600 type macroporous adsorptive resins on the filtrate, earlier with 3 times of column volume water elutions, 3 times of column volume 50% ethanol elutions of reuse are collected ethanol elution, and concentrating under reduced pressure in 60 ℃ of vacuum dryings, gets Cutis Bufonis extract 3.5g.
Embodiment 3:
Get dry maxima skin 500g, clean, add 6 times of amount 85% acetone and soaked 2 hours, reflux, extract, 60 minutes is put cold filtration, and residue adds 6 times of amount 85% acetone reflux, extract, 50 minutes, puts cold filtration, merging filtrate.
Filtrate decompression is concentrated into no acetone flavor, adds to be equivalent to 2 times of water gaging dissolvings of medical material, places 24 hours, filters.
DM301 macroporous adsorptive resins on the filtrate, earlier with 2 times of column volume water elutions, 3 times of column volume 60% ethanol elutions of reuse are collected ethanol elution, and concentrating under reduced pressure in 60 ℃ of vacuum dryings, gets Cutis Bufonis extract 2.7g.
Embodiment 4:
Get dry maxima skin 500g, clean, add 6 times of amount 85% soak with ethanol 2 hours, reflux, extract, 60 minutes.Put cold filtration, residue adds 5 times of amount 85% alcohol reflux 50 minutes, puts coldly, filters merging filtrate.
Filtrate decompression is concentrated into does not have the alcohol flavor, adds to be equivalent to 1.5 times of water gaging dissolvings of medical material, places 24 hours, filters.
HPD-400 macroporous adsorptive resins on the filtrate, earlier with 3 times of column volume water elutions, 3.5 times of column volume 50% ethanol elutions of reuse are collected ethanol elution, and concentrating under reduced pressure in 60 ℃ of vacuum dryings, gets Cutis Bufonis extract 3.1g.
Embodiment 5:
Get dry maxima skin 500g, clean, add 6 times of amount 85% methanol and soaked reflux, extract, 60 minutes 2 hours.Put cold filtration, residue adds 5 times of amount 85% methanol eddies and extracted 50 minutes, puts coldly, filters merging filtrate.
Filtrate decompression is concentrated into does not have the alcohol flavor, adds to be equivalent to 2 times of water gaging dissolvings of medical material, places 24 hours, filters.
DM301 macroporous adsorptive resins on the filtrate, earlier with 2 times of column volume water elutions, 3 times of column volume 50% ethanol elutions of reuse are collected ethanol elution, and concentrating under reduced pressure in 60 ℃ of vacuum dryings, gets Cutis Bufonis extract 3.3g.
Embodiment 6:
Get dry maxima skin 500g, clean, add 6 times of 85% acetone and soaked 2 hours, reflux, extract, 60 minutes is put coldly, filters, and residue adds 5 times of amount 85% acetone reflux, extract, 50 minutes, puts cold filtration, merging filtrate.
Filtrate decompression is concentrated into no acetone flavor, adds to be equivalent to 2 times of water gaging dissolvings of medical material, places 24 hours, filters.
HPD-600 macroporous adsorptive resins on the filtrate, earlier with 3 times of column volume water elutions, 4 times of cylinder 60% ethanol elutions of reuse are collected ethanol elution, and concentrating under reduced pressure in 60 ℃ of vacuum dryings, gets Cutis Bufonis extract 2.8g.
Embodiment 7: HUACHANSU ZHUSHEYE
Form: Cutis Bufonis extract 1.0～5.0g
Sodium chloride 9g
Water for injection 1000ml
Preparation process: get above-mentioned Cutis Bufonis extract and pharmaceutic adjuvant, add the water for injection dissolving of newly boiling, and be diluted to prescribed volume, regulate pH5.0～8.0, filter with No. 3 sintered glass funnels, embedding, per ampoule dress 2ml, sterilization, promptly.
Embodiment 8: the cinobufacin transfusion
Form: Cutis Bufonis extract 1.0～5.0g
Sodium chloride 45g
Water for injection 5000ml
Preparation process: get above-mentioned Cutis Bufonis extract and pharmaceutic adjuvant, add the water for injection dissolving of newly boiling, and be diluted to prescribed volume, regulate pH5.0～8.0, with 0.20～0.80 μ m filtering with microporous membrane, fill, every bottled 250ml, sterilization, promptly.
Embodiment 9: the injection cinobufogenin freeze-drying powder injection
Form: Cutis Bufonis extract 1.0～5.0g
Mannitol 100～200g
The husky nurse 2～8g of pool network
Preparation process: get above-mentioned Cutis Bufonis extract and pharmaceutic adjuvant, add the water for injection dissolving of newly boiling, and be diluted to 2000ml, regulate pH5.0～8.0, with 0.20～0.80 μ m filtering with microporous membrane, in 500 cillin bottles of fill, lyophilization, promptly.
Claims (4)
1, a kind of Cutis Bufonis extract, the content that it is characterized in that indoles alkaloid in the described extract is 25%～40%, cinobufagin and bufogenin total amount are 0.01%～0.05%.
2. the Chinese medicine preparation of the described Cutis Bufonis extract of claim 1 is characterized in that described Chinese medicine preparation is is the medicine active ingredient with described Cutis Bufonis extract, adds injection, infusion solution, the powder ampoule agent for injection made behind the pharmaceutic adjuvant.
3, the preparation method of Cutis Bufonis extract according to claim 1 is characterized in that operating as follows:
A, get dry maxima skin, clean, add 6～7 times of amount 85% methanol or ethanol or acetone and soaked 2 hours, reflux, extract, 60 minutes is put coldly, filters, and residue adds 5～6 times of amount 85% methanol or ethanol or acetone, and reflux, extract, 50 minutes is put coldly, filters merging filtrate;
B, step a gained filtrate add the water that is equivalent to 1～2 times of amount of medical material amount and dissolve through being evaporated to solvent-free flavor, leave standstill 24 hours after-filtration;
C, step b gained filtrate are gone up macroporous adsorptive resins, adopt Semi-polarity or polar macroporous adsorption resin, earlier with 2～3 times of column volume water elutions, 3～4 times of column volume 50%～65% ethanol elutions of reuse are collected ethanol elution, concentrating under reduced pressure, 60 ℃ of vacuum dryings get Cutis Bufonis extract.
4, according to claims 3 described preparation methoies, it is characterized in that described Semi-polarity or polar macroporous adsorption resin are polystyrene type or crosslink propylene resinae, comprise HPD-400, DM301 or HPD-600, granularity is 0.3mm～1.25mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200610096075XA CN1931190A (en) | 2006-09-13 | 2006-09-13 | Toad skin extract and its medicine prepn and their prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200610096075XA CN1931190A (en) | 2006-09-13 | 2006-09-13 | Toad skin extract and its medicine prepn and their prepn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1931190A true CN1931190A (en) | 2007-03-21 |
Family
ID=37877312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200610096075XA Pending CN1931190A (en) | 2006-09-13 | 2006-09-13 | Toad skin extract and its medicine prepn and their prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1931190A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210710A (en) * | 2011-05-31 | 2011-10-12 | 中国人民武装警察部队医学院 | Bufo bufo gargarizans cantor skin extract gelskeleton sustained-release tablets and preparation method thereof |
| CN102302476A (en) * | 2011-06-02 | 2012-01-04 | 张振海 | Dehydrobufotenine dry power inhaler and preparation method and application thereof |
| CN102973604A (en) * | 2011-06-02 | 2013-03-20 | 江苏省中医药研究院 | Toad skin extract dry powder inhalant and preparation method and applications thereof |
| CN103070885A (en) * | 2011-06-02 | 2013-05-01 | 江苏省中医药研究院 | Toad skin extract dry-powder inhalant and its preparation method and use |
| CN104840488A (en) * | 2015-05-13 | 2015-08-19 | 内蒙古康恩贝药业有限公司 | Traditional Chinese medicine toad venom dissimlar extract and preparation method thereof |
-
2006
- 2006-09-13 CN CNA200610096075XA patent/CN1931190A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210710A (en) * | 2011-05-31 | 2011-10-12 | 中国人民武装警察部队医学院 | Bufo bufo gargarizans cantor skin extract gelskeleton sustained-release tablets and preparation method thereof |
| CN102210710B (en) * | 2011-05-31 | 2013-01-23 | 中国人民武装警察部队后勤学院 | Bufo bufo gargarizans cantor skin extract gelskeleton sustained-release tablets and preparation method thereof |
| CN102302476A (en) * | 2011-06-02 | 2012-01-04 | 张振海 | Dehydrobufotenine dry power inhaler and preparation method and application thereof |
| CN102973604A (en) * | 2011-06-02 | 2013-03-20 | 江苏省中医药研究院 | Toad skin extract dry powder inhalant and preparation method and applications thereof |
| CN103070885A (en) * | 2011-06-02 | 2013-05-01 | 江苏省中医药研究院 | Toad skin extract dry-powder inhalant and its preparation method and use |
| CN102302476B (en) * | 2011-06-02 | 2013-09-25 | 张振海 | Dehydrobufotenine dry power inhaler and preparation method and application thereof |
| CN103070885B (en) * | 2011-06-02 | 2014-08-27 | 江苏省中医药研究院 | Toad skin extract dry-powder inhalant and its preparation method and use |
| CN102973604B (en) * | 2011-06-02 | 2015-05-27 | 江苏省中医药研究院 | Toad skin extract dry powder inhalant and preparation method and applications thereof |
| CN104840488A (en) * | 2015-05-13 | 2015-08-19 | 内蒙古康恩贝药业有限公司 | Traditional Chinese medicine toad venom dissimlar extract and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857421A (en) | Preparing method of total corydaline extract and corydalis preparation | |
| CN1931190A (en) | Toad skin extract and its medicine prepn and their prepn | |
| CN1899491A (en) | Method for preparing paris polyphylla total saponin and its use | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1698803A (en) | Compound notoginseng injection and its preparation process | |
| CN1285344C (en) | Method for preparing acanthopanax injectio | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN1686464A (en) | Radix dactylicapni injection and its preparation method | |
| CN1631902A (en) | Angelica polysaccharide and its preparation and use | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN1522746A (en) | Gadol pharmaceutical preparation, method for making same and uses | |
| CN1264506C (en) | Pharmaceutical combination containing red sage root element and preparation method thereof | |
| CN1546124A (en) | Freeze-dried 'Shengmai' powder for injection and its preparing process | |
| CN1730014A (en) | Novel drug administration route of semen armeniacae amarum injection, its preparation process and new indications | |
| CN1730009A (en) | Novel drug administering route of ginseng stem and leave general saponin and its preparation process and new indications | |
| CN1872101A (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, distilling method and application | |
| CN1785212A (en) | Novel cinobufogenin freeze-drying powder injection, its prepn. method and quality control method | |
| CN1234399C (en) | Method for preparing mailuoning freeze-dried powder for injection | |
| CN1548079A (en) | Active part and effective component of Four Drug Decoction | |
| CN1768762A (en) | Novel drug administering route of pantocrine injection, its preparation process and novel indications | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1273114C (en) | Sichuan aconite root freeze-dried powder injection and its preparing method | |
| CN1297278C (en) | Medicinal composition containing salvianolic acid B, total ara-saponin and camphol and its preparation and use | |
| CN1283650C (en) | Process of extracting total flavone glycoside from mistletoe and medicine composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070321 |